Therapeutic Innovations: Tyrosine Kinase Inhibitors in Cancer

dc.contributor.authorDervisis, Nikolaos G.en
dc.contributor.authorKlahn, Shawna L.en
dc.date.accessioned2016-10-18T10:24:28Zen
dc.date.available2016-10-18T10:24:28Zen
dc.date.issued2016-01-20en
dc.description.abstractConventional cytotoxic chemotherapy involving DNA-interacting agents and indiscriminate cell death is no longer the future of cancer management. While chemotherapy is not likely to completely disappear from the armamentarium; the use of targeted therapies in combination with conventional treatment is becoming the standard of care in human medicine. Tyrosine kinases are pivotal points of functional cellular pathways and have been implicated in malignancy, inflammatory, and immune-mediated diseases. Pharmaceutical interventions targeting aberrant tyrosine kinase signaling has exploded and is the second most important area of drug development. The “Valley of Death” between drug discovery and approval threatens to blunt the enormous strides in cancer management seen thus far. Kinase inhibitors, as targeted small molecules, hold promise in the treatment and diagnosis of cancer. However, there are still many unanswered questions regarding the use of kinase inhibitors in the interpretation and management of cancer. Comparative oncology has the potential to address restrictions and limitations in the advancement in kinase inhibitor therapy.en
dc.description.versionPublished versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.citationDervisis, N.; Klahn, S. Therapeutic Innovations: Tyrosine Kinase Inhibitors in Cancer. Vet. Sci. 2016, 3, 4.en
dc.identifier.doihttps://doi.org/10.3390/vetsci3010004en
dc.identifier.issueComparative Pathogenesis of Cancers in Animals and Humansen
dc.identifier.urihttp://hdl.handle.net/10919/73239en
dc.language.isoenen
dc.publisherMDPIen
dc.rightsCreative Commons Attribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.subjecttyrosine kinase inhibitorsen
dc.subjectcomparativeen
dc.subjectcanceren
dc.subjectchemotherapyen
dc.subjectdogen
dc.subjectcaten
dc.subjecthumanen
dc.titleTherapeutic Innovations: Tyrosine Kinase Inhibitors in Canceren
dc.title.serialVeterinary Sciencesen
dc.typeArticle - Refereeden
dc.typeReviewen
dc.type.dcmitypeTexten
pubs.organisational-group/Virginia Techen
pubs.organisational-group/Virginia Tech/All T&R Facultyen
pubs.organisational-group/Virginia Tech/Faculty of Health Sciencesen
pubs.organisational-group/Virginia Tech/Veterinary Medicineen
pubs.organisational-group/Virginia Tech/Veterinary Medicine/CVM T&R Facultyen
pubs.organisational-group/Virginia Tech/Veterinary Medicine/Small Animal Clinical Sciencesen
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Therapeutic Innovations- Tyrosine Kinase Inhibitors.pdf
Size:
519.3 KB
Format:
Adobe Portable Document Format
Description:
Publisher's Version
License bundle
Now showing 1 - 1 of 1
Name:
VTUL_Distribution_License_2016_05_09.pdf
Size:
18.09 KB
Format:
Adobe Portable Document Format
Description: